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A role of y-interferon In the bone remodelmg process can be lmphcated from Its interference with bone re- 
sorptlve processes m cultured neonatal mouse calvarla The Immune Interferon IS an efflclent mhlbltor of 
endogenous prostaglandm synthesis, particularly after stlmulatlon by thrombm or arachldomc acid, and, 
m addltlon, has a calatonm-hke mhlbltory effect on PTH-Induced osteoclastlc bone resorption 
y-Interferon Bone resorption Neonatal mouse calvarra Prostaglandm synthesis Parathyrord hormone 
Calcitonrn 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Interleukms and lymphokmes may play a role m 
the bone remodeling process [l], particularly 
through the bone resorbing actrvmes of interleukm 
1 [2] and of the so-called ‘osteoclast activating fac- 
tor’ [3] which is elaborated by T-lymphocytes m 
response to various stimuli, among them probably 
also mterleukin 1 [l]. y-Interferon (IFN-y) which 
like other lymphokmes is produced by lym- 
phocytes following proliferative or specific an- 
tigemc strmulation (cf. [4]), induces polykaryon 
formation in cultured human monocytes [5]. It 1s 
thus concervable that IFN-y could also induce the 
formation of multmuclear osteoclasts, which are 
believed to normally originate through fusion from 
monocyte precursor cells (cf. [l]), and could 
possibly thereby induce the resorption of 
mineralized bone. We therefore have utilized the 
organ culture system of neonatal mouse calvaria to 
study potential effects of IFN-y on osteoclastic 
bone resorption. 
Recombinant DNA-derived murme IFN-y 
(Genentech, CA, spec. act. 1.3 x lo7 U/mg) was 
obtained through Ernst Boehrmger-Instttut fur 
Arznermtttelforschung, Vienna. Synthetic salmon 
calcrtonm (spec. act. 100 MRC units/ml) was pur- 
chased from Sanabo (Vienna). Parathyrord hor- 
mone (PTH) was a synthetic human N-terminal 
fragment l-34 from Bachem, Torrance, CA. 
Prostaglandm EZ (PGE2) was purchased as Pros- 
tm Ez@ from UpJOhn Bovine thrombin 
(Topostasm@ ) is a product of Hoffmann- 
LaRoche (Basle). Indomethacm was obtamed 
from Merck, Sharp and Dohme. 
Organ culture of neonatal mouse calvaria has 
been described m detail [7,8]. Briefly, calvartae 
were dissected from 4-6-day-old mice (strain 
HIM : OFI, SPF, Institute for Experimental 
Animal Research of the University of Vienna, 
Htmberg) and cultured free-floating in roller tubes 
m Dulbecco’s modified Eagle’s medium (sup- 
plemented with 15 070 heat-inactivated horse 
serum). Treatments were begun at 0 h and con- 
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tmued to 72 or 96 h, as appropriate. Medium was 
changed at 24 h. Bone resorption was quantltated 
by determination of calcium concentration m 
culture medium at 24 h intervals through 
fluorescence titration in a Corning 940 calcium 
analyzer. 
Data are presented as means (from 5 
calvanae) + SE. Student’s t-test was used for 
statistIca analysis Slgmflcant differences between 
groups were assumed when P < 0 05 
3. RESULTS 
In bones maintained m organ culture wlthout 
any treatment, the rate of resorption shghtly ex- 
ceeds that of formation of mmerahzed bone, as m- 
dlcated by the contmuous release of calcmm into 
the medium (fig 1, controls). This process can be 
inhibited by mdomethacm (flg.1, cf. [8]), and 1s 
therefore believed to be determmed m Its extent by 
the production rate of endogenous prostaglandms 
[8], which are potent inducers of osteoclast actlvlty 
m bone culture [6] Fig.1 shows that addition of 
IFN-7 to the culture medium (at 100 U/ml) 
slgmficantly reduces the amount of calcmm 
mobilized from cultured calvarlae In these ex- 
periments, the mhlbltory actlon of IFN-7 on bone 
resorption could not be dlstmgmshed from that of 
salmon calcltonm (sCT) or mdomethacm (fig 1). 
In a series of experiments we therefore addressed 
the question as to whether IFN-1 could Interact 
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Fig 1 Effect of IFN-3 on calcium release from cultured 
neonatal mouse calvarla Medium concentrations IFN- 
7, 100 U/ml, salmon calcltonm (sCT), 20 mu/ml, 
mdomethacm, S x lo-’ M Arrow mdlcates change of 
culture medium Treated groups were sigmficantly 
different from untreated controls at least at P < 0 05 at 
48 and 12 h 
with prostaglandm (PG) syntheslzmg reactions m 
bone. The latter can be efficiently stimulated 
through contmuous exposure of bone to moderate 
actlvltles of thrombm m organ culture [9]. In this 
experimental condltlon, which has been designed 
to evaluate speciflcally the blopotency of mhlbltors 
of prostaglandm synthesis m bone (unpublished), 
IFN-y proves to be as potent an mhlbltor of 
prostaglandm-mediated bone resorption as, e.g., 
mdomethacm [9] (flg.2). That IFN-y thereby does 
not interfere with thrombm actlvatlon of pros- 
taglandm synthesis but rather with the cycloox- 
ygenase system itself can be concluded from the 
observation that IFN-7 displays its inhibitory 
potency when resorption of cultured bones by 
prostaglandms 1s faclhtated by addition of their 
precursor arachldomc acid (5 x 10m5 M) to the 
culture medium [8] (flg.2) 
It should be noted that calcltomn had no effect 
on calcium release from bones stimulated by 
thrombm or arachldomc acid (not shown). 
Consistent with its proposed mechanism of ac- 
tion on prostaglandm synthesis, IFN-7, at the 
100 U/ml level, did not substantially reduce bone 
resorption evoked by exogenous PGE2 (5 x 
40 
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Fig 2 Effect of IFN-7 on calcium release from cultured 
bone stimulated by thrombm, arachldomc acid (AA), or 
PGEz Medium concentrations IFN-y, 100 U/ml, 
thrombm, 14 U/ml, arachldomc acid, 5 x lo-’ M, 
PGEz, 5 x IO-' M Medium Indicates change of culture 
medmm IFN-7 treatment resulted m slgmflcant 
differences from respectwe control groups (P < 0 05) at 
48 and 72 h 
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1tX7 M), though m the presence of IFN-7 less 
calcmm was mobtlized by PGEz than could have 
been expected rf IFN-y ~nhlblted endogenous PG 
formation only (fig.2). 
This observation led us to pursue the questton of 
whether IFN-y, eventually at htgher concentra- 
tions, could mhibrt osteoclastrc bone resorption, 
posstbly by interference with the recrurtment 
and/or acttvatron of osteoclasts Thts phenome- 
non occurs either as result of PC action [6] or 
through an independent effect of PTH on 
osteoclasts and thetr mononuclear precursors in 
cultured bone [IO,1 I]. In fact, IFN-y, partrcularly 
at htgher medium levels, substantially reduced 
calcium release induced by IO-’ M PTH, which 
was shown to be the maxrmally effectrve concen- 
tration m the mouse calvarra system [7]. This effect 
of IFN-y was quite comparable to the antagomstrc 
action of calcnonm on PTH-induced bone resorp- 
tron 1121 (fig.3). 
4. DISCUSSION 
Thrs study presents expertmental evidence for a 
potentral lnhibltory effect of IFN-7 on bone 
resorptton m vrvo Immune mterferon might thus 
play a role in the bone remodeling process, 
prrmartly by suppression of PG formatton, though 
an addrtronal, calcrtonm-like effect on PTH- 
24 48 12 91 noucr 
Fig 3 Effect of IFN-7 on PTH-mduced bone resorption 
m cultured neonatal mouse calvarla Medmm 
concentrations: PTH, lo-’ M, KT, 20 mu/ml Arrow 
mdlcates change of culture medmm IFN-7 and sCT- 
treated groups showed statlstlcally signIf]cant difference 
from PTH-treated group between 48 and 96 h (P < 
0 05) 
induced osteoclast activatton must also be con- 
sidered a likely possrbrlrty. With respect o PG syn- 
thesrs, IFN-y could counteract he osteolytic actrvi- 
ty of other lmmu~oregulatory factors such as in- 
terleukin 1 and osteoclast actrvatmg factor, which 
both are effective, at least in part, vta sttmulatron 
of PC formation [2,13]. 
Untrl now tt has been generally assumed that m- 
terferons, parttcularly those of the a+ and .&type, 
would increase rather than decrease PG syntheses 
m vartous ttssues 1141. Notably, recombmant 
human LY- and ,&nterferon have been shown to in- 
crease PGEz levels in the hypothalamus [151, thus 
provrdmg an explanation why fever 1s a common 
srde effect of interferon therapy. However, a drf- 
ferent srtuatton mtght prevarl m bone. Jtlka and 
Hamilton [16] drd not observe any bone resorbmg 
activity when neonatal mouse calvarra m organ 
culture was treated wtth a human leukocyte m- 
terferon. In addrtmn, N&son et al. 1181 obtained 
no indication for a bone resorbmg effect of mouse 
C-243 cell Interferon on heterotoptc bone Implants 
in mice 
The calcttomn-like ffect of IFN-y IS difficult to 
interpret rf one assumes that the immune in- 
terferon actually brings about the fusion of 
monocytes into osteoclasts If this actually oc- 
curred m bone this would force the conclusron that 
these cells cannot be actrvated m the presence of 
IFN-r This could also explam the reduced effec- 
tivity of PTH m the presence of the rmmune m- 
terferon observed m our expertments Srmtlar con- 
clusrons pertain to a comparable action of a 
recombmant human leukocyte IFN on PTH- 
mduced bone resorption [16] 
The ability of IFN-y to block PG brosynthesrs in 
bone could be explotted for treatment of tumors 
that stimulate bone resorption by etther increasing 
crrculatmg levels of PGs or more directly then for- 
matron m bone (cf. [Is]), IFN-7 mrght also be 
useful m the treatment of various mflammatory 
diseases associated with localized PG-mediated 
bone destructton, parttcularly rheumatord ar- 
thrrtrs. However, the therapeutrcal value of IFN-y 
could be dtmmrshed by the possrbrhty that m this 
autoimmune-related isorder, IFN-y, under cer- 
tam condrtrons, could even enhance antibody pro- 
duction as well as delayed type hypersensitivity 
reactions (cf. 141). Treatment of osteoporosrs wtth 
IFN-y instead of or m combsnation with calcnomn 
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might also be promising for the followmg reason. 
In osteoporosrs, bone resorptton undoubtedly ex- 
ceeds the formation of new bone [I91 There IS 
some evtdence that thus mtght be partially due to an 
enhanced local productron of PGEz m bone [201 
Thus, IFN-y, unhke calcrtonm, could certamiy 
block any PC-medrated bone destruction and, n-t 
addmon, through Its calcnonin-hke effect even 
further reduce the rate of osteoclastrc bone 
resorptron 
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